Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Celularity Inc. (Nasdaq: CELU), a clinical-stage biotech firm in Florham Park, N.J., is advancing placental-derived allogeneic cell therapies aimed at cancer and other diseases. On March 17, 2022, at 11:20 AM ET, CEO Robert Hariri and President Andrew Pecora will engage in a fireside chat during the Oppenheimer 32nd Annual Healthcare Conference. This event can be accessed via a live webcast on Celularity’s website, with a replay available for 30 days. Celularity focuses on innovative therapies utilizing natural killer cells and CAR T-cells, addressing global health needs.

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies for cancer, infectious and degenerative diseases, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Andrew Pecora, M.D., President of Celularity, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 11:20am ET.

A live webcast of the fireside chat can be accessed on the Investors section of Celularity’s website at https://celularity.com/investor-relations/. A replay of the webcast will be archived and available following the event for approximately 30 days.

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Celularity Investor Contacts:

Carlos Ramirez SVP, Investor Relations
Celularity Inc.
carlos.ramirez@celularity.com

 

FAQ

When is the Oppenheimer 32nd Annual Healthcare Conference featuring Celularity executives?

The Oppenheimer 32nd Annual Healthcare Conference will take place on March 17, 2022, at 11:20 AM ET.

How can I watch the Celularity fireside chat at the conference?

You can watch the Celularity fireside chat live through the Investors section of Celularity’s website.

What will Celularity discuss during the Oppenheimer conference?

Celularity will discuss its placental-derived off-the-shelf cell therapies for cancer and other diseases.

What is Celularity's focus in biotechnology?

Celularity focuses on developing allogeneic cryopreserved cell therapies and innovative biomaterials from the placenta.

How long will the replay of the Celularity webcast be available?

The replay of the Celularity webcast will be available for approximately 30 days after the event.